Search research articles
Contact Us
Filters
Showing results (61-70 of 67) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 67 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2013
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
W Schmiegel, A Reinacher-Schick, D Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation
H J Schlitt, M Neipp, A Weimann, et al.
ESMO Open
|
February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]
R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open
|
September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)
R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open
|
June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial
G Stocker, S Lorenzen, T Ettrich, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 67) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 67 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 7, 2013
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
W Schmiegel, A Reinacher-Schick, D Arnold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation
H J Schlitt, M Neipp, A Weimann, et al.
ESMO Open
|
February 22, 2025
Corrigendum to "mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06)": [ESMO Open 9 (2024) 103703]
R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open
|
September 11, 2024
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214)
R-D Hofheinz, F Herrle, T Dechow, et al.
ESMO Open
|
June 4, 2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial
G Stocker, S Lorenzen, T Ettrich, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
Page
of 7